Moreover, HDAC inhibitors decreased death of motor neurons, enhanced motor performance, increased the survival time and resulted in life extension in a mice model of amyotrophic lateral sclerosis [137], restored fear learning, decreased Aβ accumulation and improved cognitive performance in mouse models of Alzheimer’s disease [138,139] and generated neuroprotection in a model of Parkinson’s disease [140]. This evidence concerns the gene HDAC9 and early-onset autosomal dominant Alzheimer disease.